TBPH icon

Theravance Biopharma

125 hedge funds and large institutions have $1.11B invested in Theravance Biopharma in 2020 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 42 increasing their positions, 28 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more funds holding

Funds holding:

less ownership

Funds ownership:

15% less capital invested

Capital invested by funds: $1.32B → $1.11B (-$203M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

96% less call options, than puts

Call options by funds: $39K | Put options by funds: $1.03M

Holders
125
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$39K
Puts
$1.03M
Net Calls
Net Calls Change

Top Sellers

1 -$92.4M
2 -$23.1M
3 -$7.03M
4
Morgan Stanley
Morgan Stanley
New York
-$3.05M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$2.01M
Name Holding Trade Value Shares
Change
Change in
Stake
26
$5.13M
27
$4.8M
28
$4.53M
29
$4.52M
30
$3.78M
31
$3.61M
32
$3.59M
33
$3.3M
34
$2.48M
35
$2.37M
36
$2.16M
37
$2.1M
38
$2.04M
39
$2.02M
40
$1.99M
41
$1.96M
42
$1.93M
43
$1.79M
44
$1.64M
45
$1.63M
46
$1.57M
47
$1.55M
48
$1.55M
49
$1.5M
50
$1.49M